DEXCOM INC

NASDAQ: DXCM (DexCom, Inc.)

Last update: 06 Jan, 4:38PM

69.89

2.24 (3.31%)

Previous Close 67.65
Open 67.65
Volume 3,966,079
Avg. Volume (3M) 5,795,374
Market Cap 27,407,730,688
Price / Earnings (TTM) 38.83
Price / Earnings (Forward) 28.57
Price / Sales 6.39
Price / Book 10.13
52 Weeks Range
54.11 (-22%) — 93.25 (33%)
Earnings Date 30 Oct 2025
Profit Margin 12.90%
Operating Margin (TTM) 12.91%
Diluted EPS (TTM) 1.33
Quarterly Revenue Growth (YOY) 12.50%
Quarterly Earnings Growth (YOY) -28.00%
Total Debt/Equity (MRQ) 113.97%
Current Ratio (MRQ) 1.50
Operating Cash Flow (TTM) 964.10 M
Levered Free Cash Flow (TTM) 509.04 M
Return on Assets (TTM) 5.97%
Return on Equity (TTM) 23.72%

Market Trend

Short Term Medium Term
Industry Medical Devices (US) Mixed Mixed
Medical Devices (Global) Mixed Mixed
Stock DexCom, Inc. Bearish Bearish

AIStockmoo Score

-0.3
Analyst Consensus -0.5
Insider Activity 3.0
Price Volatility -2.0
Technical Moving Averages -2.5
Technical Oscillators 0.5
Average -0.30

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
DXCM 27 B - 38.83 10.13
PODD 21 B - 86.12 13.04
SSII 1 B - - 20.66
IRTC 6 B - - 42.64
TMDX 5 B - 55.88 13.56
ESTA 2 B - - 122.85

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

Sector Healthcare
Industry Medical Devices
Investment Style Mid Growth
% Held by Insiders 0.42%
% Held by Institutions 97.10%
52 Weeks Range
54.11 (-22%) — 93.25 (33%)
Price Target Range
68.00 (-2%) — 90.00 (28%)
High 90.00 (Argus Research, 28.77%) Buy
Median 77.00 (10.17%)
Low 68.00 (Evercore ISI Group, -2.70%) Hold
Average 77.86 (11.40%)
Total 5 Buy, 1 Hold, 1 Sell
Avg. Price @ Call 64.89
Firm Date Target Price Call Price @ Call
Barclays 12 Jan 2026 71.00 (1.59%) Sell 70.98
Bernstein 09 Jan 2026 86.00 (23.05%) Buy 67.40
Mizuho 17 Dec 2025 78.00 (11.60%) Buy 65.75
Citigroup 11 Dec 2025 77.00 (10.17%) Buy 68.94
Morgan Stanley 02 Dec 2025 75.00 (7.31%) Buy 64.45
10 Nov 2025 63.00 (-9.86%) Hold 54.84
Evercore ISI Group 25 Nov 2025 68.00 (-2.70%) Hold 61.69
Argus Research 07 Nov 2025 90.00 (28.77%) Buy 55.00
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
BROWN MICHAEL JON 74.00 74.00 4,470 330,780
LEACH JACOB STEVEN 74.00 74.00 5,252 388,648
SAYER KEVIN R 74.00 74.00 36,961 2,735,114
STERN SADIE 74.00 74.00 4,467 330,558
SYLVAIN JEREME M 74.00 74.00 4,471 330,854
Aggregate Net Quantity 55,621
Aggregate Net Value ($) 4,115,954
Aggregate Avg. Buy ($) 74.00
Aggregate Avg. Sell ($) 74.00
Name Holder Date Type Quantity Price Value ($)
SAYER KEVIN R Officer 29 Jan 2026 Acquired (+) 71,218 74.00 5,270,132
SAYER KEVIN R Officer 29 Jan 2026 Disposed (-) 34,257 74.00 2,535,018
SYLVAIN JEREME M Officer 29 Jan 2026 Acquired (+) 7,123 74.00 527,102
SYLVAIN JEREME M Officer 29 Jan 2026 Disposed (-) 2,652 74.00 196,248
BROWN MICHAEL JON Officer 29 Jan 2026 Acquired (+) 7,123 74.00 527,102
BROWN MICHAEL JON Officer 29 Jan 2026 Disposed (-) 2,653 74.00 196,322
STERN SADIE Officer 29 Jan 2026 Acquired (+) 7,123 74.00 527,102
STERN SADIE Officer 29 Jan 2026 Disposed (-) 2,656 74.00 196,544
LEACH JACOB STEVEN Officer 29 Jan 2026 Acquired (+) 8,310 74.00 614,940
LEACH JACOB STEVEN Officer 29 Jan 2026 Disposed (-) 3,058 74.00 226,292
Date Type Details
04 Feb 2026 Announcement Stelo Adds Enhanced Smart Meal Logging Features as Dexcom Continues to Transform Personal Glucose Management
27 Jan 2026 Announcement Dexcom Schedules Fourth Quarter and Fiscal Year 2025 Earnings Release and Conference Call for February 12, 2026 at 4:30 p.m. Eastern Time.
12 Jan 2026 Announcement Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook
07 Jan 2026 Announcement Dexcom Enters Next Era of Continued Innovation With Jake Leach as President and Chief Executive Officer
26 Dec 2025 Announcement Latest SueWallSt Podcast: What DXCM Investors Need to Know About the Lawsuit
23 Dec 2025 Announcement Tune Into the SueWallSt Podcast: DexCom, Inc. (DXCM) Lawsuit Explained
22 Dec 2025 Announcement Shareholders SueWallSt in New Class Action Against DexCom, Inc. - Act Now
19 Dec 2025 Announcement Investors SueWallSt as DexCom, Inc. Faces Securities Fraud Allegations
18 Dec 2025 Announcement DexCom, Inc. (DXCM) Shareholders Get Answers in Latest SueWallSt Podcast
17 Dec 2025 Announcement Latest SueWallSt Podcast: What DXCM Investors Need to Know About the Lawsuit
16 Dec 2025 Announcement DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
15 Dec 2025 Announcement Shareholders SueWallSt in New Class Action Against DexCom, Inc. - Act Now
15 Dec 2025 Announcement DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
12 Dec 2025 Announcement SueWallSt Podcast Explains Class Action Against DexCom, Inc. (DXCM)
11 Dec 2025 Announcement DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
09 Dec 2025 Announcement Shareholders SueWallSt in New Class Action Against DexCom, Inc. - Act Now
09 Dec 2025 Announcement DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
09 Dec 2025 Announcement DexCom, Inc. (DXCM) Shareholders Get Answers in Latest SueWallSt Podcast
08 Dec 2025 Announcement DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
08 Dec 2025 Announcement DexCom, Inc. (DXCM) Shareholders Get Answers in Latest SueWallSt Podcast
05 Dec 2025 Announcement SueWallSt Podcast Series Launches With Focus on DexCom, Inc. (DXCM) Fraud Allegations
05 Dec 2025 Announcement Shareholders SueWallSt in New Class Action Against DexCom, Inc. - Act Now
04 Dec 2025 Announcement Shareholders SueWallSt in New Class Action Against DexCom, Inc. - Act Now
04 Dec 2025 Announcement Listening to Healthcare Professionals: Dexcom Launches New Education Offering, Dexcom Academy
04 Dec 2025 Announcement DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
03 Dec 2025 Announcement Investors SueWallSt as DexCom, Inc. Faces Securities Fraud Allegations
02 Dec 2025 Announcement DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
02 Dec 2025 Announcement Tune Into the SueWallSt Podcast: DexCom, Inc. (DXCM) Lawsuit Explained
01 Dec 2025 Announcement DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
01 Dec 2025 Announcement Tune Into the SueWallSt Podcast: DexCom, Inc. (DXCM) Lawsuit Explained
25 Nov 2025 Announcement DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
25 Nov 2025 Announcement GlucoGuard a Division of American Diversified Holdings (ADHC) Successfully Submits Level 2 App Integration Through Dexcom's Developer Partner Program
24 Nov 2025 Announcement DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
20 Nov 2025 Announcement Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States
20 Nov 2025 Announcement DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
19 Nov 2025 Announcement Dexcom Smart Basal Receives FDA Clearance Becoming the First and Only CGM-integrated Basal Insulin Dosing Optimizer for Type 2 Diabetes
18 Nov 2025 Announcement Investors SueWallSt as DexCom, Inc. Faces Securities Fraud Allegations
18 Nov 2025 Announcement DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
17 Nov 2025 Announcement Investors SueWallSt as DexCom, Inc. Faces Securities Fraud Allegations
14 Nov 2025 Announcement Dexcom Reveals Global Diabetes Advocates: New Voices for Diabetes Awareness This World Diabetes Day
06 Nov 2025 Announcement Québec Expands Access to Dexcom CGM under the Régie de l'assurance maladie du Québec (RAMQ)
06 Nov 2025 Announcement Shareholders SueWallSt in New Class Action Against DexCom, Inc. - Act Now
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria